Acadia seeks regulatory approval in EU of trofinetide for Rett
Acadia is seeking regulatory approval in the European Union of trofinetide, sold in the U.S. as Daybue, for patients with Rett syndrome.| Rett Syndrome News
Acadia is seeking regulatory approval in the European Union of trofinetide, sold in the U.S. as Daybue, for patients with Rett syndrome.| Rett Syndrome News
Trofinetide significantly reduced neurobehavioral symptoms and improved communication in females with Rett syndrome, the LAVENDER trial shows.| Rett Syndrome News
